Regulatory News
Wednesday, July 6, 2016
BRIEF-Revive Therapeutics announces U.S. FDA acceptance of IND of Bucillamine for treatment of cystinuria
* Revive therapeutics Ltd. announces U.S. FDA acceptance of
IND of Bucillamine for treatment of cystinuria
Source text for Eikon:
Further company coverage:
)
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment